Supplementary Material for: Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients Kaymak T. Moriconi F. Niess J.H. Beglinger C. Hruz P. 10.6084/m9.figshare.5908948.v1 https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Low_Discontinuation_Rate_of_Infliximab_Treatment_in_Steroid-Dependent_Refractory_Crohn_s_Disease_Patients/5908948 <b><i>Background:</i></b> Many patients with moderate to severe Crohn’s disease (CD) are treated with infliximab (IFX). As most of these patients experience a long-lasting therapy, the outcome and withdrawal of IFX treatment are important clinical questions. <b><i>Methods:</i></b> In this retrospective study, we analyzed the treatment outcome in moderate to severe CD patients with a steroid-dependent/refractory disease course started on IFX. Withdrawal of IFX was evaluated in patients with deep remission defined as clinical (Harvey-Bradshaw Index ≤4), biochemical (fecal calprotectin [FC] ≤150 μg/g stool) over a period of 2 years, and endoscopic and histological remission before discontinuation of IFX. <b><i>Results:</i></b> After induction with IFX, clinical remission was observed in 45/109 patients (41.3%) and clinical response in 61/109 patients (56.0%). Only 8/109 patients (7.3%) achieved deep remission and therefore could be discontinued from IFX therapy. In 4 of these patients (50%), relapse was observed after discontinuation of IFX treatment. FC decreased in these 8 patients in deep remission from 652 ± 168 μg/g stool (mean ± SE) at baseline to 24.9 ± 8.1 μg/g stool at 14 weeks. When compared to patients in deep remission, FC had decreased significantly less at 14 weeks in patients in clinical remission after induction with IFX (<i>n</i> = 31; 154 ± 55 μg/g stool; <i>p</i> = 0.01), in patients with clinical response after induction achieving clinical remission during the maintenance phase (<i>n</i> = 11; 352 ± 67 μg/g stool; <i>p</i> = 0.004), or in patients with chronic active disease course on maintenance therapy (<i>n</i> = 50; 645 ± 93 μg/g stool; <i>p</i> < 0.001). <b><i>Conclusion:</i></b> A low discontinuation rate was observed for steroid-dependent/refractory moderate to severe CD patients with IFX treatment. As FC showed a more or less pronounced decrease depending on the response to the IFX treatment, monitoring of FC may become a noninvasive tool for tailoring biological therapy in CD patients. 2018-02-21 08:01:35 Crohn’s disease Fecal calprotectin Infliximab Relapse Remission